Evidence map›Paper›PMID 36381804›Full record

ReviewCureus2022

Role of High-Sensitivity C-reactive Protein (Hs-CRP) in Non-communicable Diseases: A Review.

Tanvi Banait, Anil Wanjari, Vedika Danade, Shashank Banait, Jyoti Jain

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07513922 (Correlation Between hs CRP TG Triglycerides Glucose Index in NAFLD and Liver Fibrosis), which is not on this map. Cited by 80 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 6 pooled it
14.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07513922 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Correlation Between hs CRP TG Triglycerides Glucose Index in NAFLD and Liver Fibrosis

Typeobservational_patient_registrySponsorAssiut UniversityRan2026 to 2027Enrolled96ConditionsLiver FibrosisArms• Fasting triglycerides (TG) • Fasting plasma glucose • High-sensitivity C-reactive protein (hs-CRP) • Liver enzymes (ALT, AST, GGT) • Platelet count • HbA1c • Lipid profile (total cholesterol, HDL-C,
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Recent Advances in Aptamer-Based Applications in Cardiology.International journal of molecular sciences · 2026
    Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tanvi BanaitInternal Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Anil WanjariInternal Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Vedika DanadeInternal Medicine, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND.
Shashank BanaitOphthalmology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, IND.
Jyoti JainInternal Medicine, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND.
Mahatma Gandhi Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-communicable diseases like cardiovascular diseases, cerebrovascular diseases, diabetes mellitus, and cancer are very common causes of death worldwide. Therefore, the need to search for novel, affordable, and easily accessible biomarkers and risk factors for non-communicable diseases continues, which can predict the future risk of having these diseases with greater accuracy and precision. In this context, among available biomarkers, high-sensitivity C-reactive protein (Hs-CRP) is considered to be the best-suited marker. Various drug intervention trials demonstrated positive results in reducing Hs-CRP in individuals with raised levels. Numerous pharmacological and non-pharmacologic interventions in the form of lifestyle modifications, exercise, and cessation of smoking are being investigated to study their effect on reducing serum C-reactive protein (CRP) levels. This review article discusses the role of Hs-CRP and its isoforms in the pathogenesis of various disease conditions, factors affecting its serum concentration, its prognostic value, and its comparison with other risk factors. Further, its clinical significance in chronic inflammatory and degenerative diseases of the nervous system and other common non-communicable diseases, including recent advances in the management of various diseases, has also been discussed.

Indexed as

acute phase reactantsc-reactive proteinhigh sensitivity c-reactive proteininflammationmolecular biomarker

Identifiers

PMID36381804
PMCPMC9650935
OpenAlexW4304698181

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.